Skip to main content

. 2022 Dec 21;66(1):1082. doi: 10.1021/acs.jmedchem.2c02002

Correction to “Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069”

Douglas L Orsi, Elisabeth Pook, Nico Bräuer, Anders Friberg, Philip Lienau, Christopher T Lemke, Timo Stellfeld, Ulf Brüggemeier, Vera Pütter, Hanna Meyer, Maria Baco, Stephanie Tang, Andrew D Cherniack, Lindsay Westlake, Samantha A Bender, Mustafa Kocak, Craig A Strathdee, Matthew Meyerson, Knut Eis, Jonathan T Goldstein ^✉

PMCID: PMC9841977 PMID: 36542814

The incorrect PDF file was provided as Supporting Information with the published article. The correct file for this paper is provided here.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.2c02002.

Methods for RNA sequencing and the PRISM multiplexed cell line panel, summary of the HTS screen, PRISM profiling, colony formation assay, RNA sequencing analysis, X-ray structural comparison of the binding modes of BAY-4931 and T0070907, pharmacodynamic analysis of tumors treated with compounds, HPLC traces of in vivo compounds, and NOESY profiles of compounds 8b and 8c (PDF)

Supplementary Material

jm2c02002_si_001.pdf^{(12.5MB, pdf)}

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

jm2c02002_si_001.pdf^{(12.5MB, pdf)}

ACTIONS

RESOURCES